ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy
ViVac Pharma has appointed Keren Leshem as its new Chief Executive Officer in a recent leadership change to advance the company’s RNA-lipid nanoparticle (RNA-LNP) cancer immunotherapy platform17.
Keren Leshem is recognized as a World Economic Forum Technology Pioneer CEO, with nearly three decades of experience in the life sciences sector1.
Prior to joining ViVac, Leshem has held senior leadership roles in multiple innovative biotech and healthcare companies, including OCON Healthcare23.
ViVac Pharma’s focus under Leshem’s leadership includes developing advanced RNA-LNP technologies targeting cancer immunotherapy, which represents a major growth area in oncology therapeutics1.
The company’s appointment of Leshem is seen as a strategic move to accelerate its research, development, and potential commercialization initiatives17.
Sources:
1. https://trial.medpath.com/news/d4f686d89bda3894/vivac-pharma-appoints-keren-leshem-as-ceo-to-advance-rna-lipid-nanoparticle-cancer-immunotherapy-platform
2. https://www.youtube.com/watch?v=35CVNSe43DQ